Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardioprotection with nebivolol in anthracycline-treated breast cancer or diffuse large B cell lymphoma patients
2017-004618-24Phase 3Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nebivolol in chemotherapy-induced cardiotoxicity (CIC) and left ventricular systolic dysfunction (LVSD) (2 arms), sponsored by Humanitas Research Hospital. Primary endpoint: Change in left ventricular ejection fraction at 12 months. Started Sep 2018; status: completed.
02
Drugs
nebivolol
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2017-004618-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004618-24.